Is the Wegovy Price Going Up? What UK Private Patients Should Know

The misconception: Wegovy's price is set by clinics and goes wherever they choose

The most common misreading is that private pharmacies and online clinics are the ones deciding whether Wegovy costs more or less. In reality, the biggest single driver is manufacturer list price. Eli Lilly's decision to raise Mounjaro's UK wholesale price sharply from 1 September 2025 drew wide attention, and it is instructive context here: manufacturer pricing can move independently of demand, and providers pass that movement on. Novo Nordisk, which makes Wegovy (semaglutide), has its own UK pricing decisions that are separate from anything a clinic controls.

Private providers also build in the cost of clinical infrastructure — prescribers' time, pharmacy regulation, dispensing, cold-chain logistics. A quoted headline price that seems low may simply be stripping those elements out and charging them separately. The full picture of what Wegovy costs in the UK tends to look different once consultation fees, prescription fees and delivery are added to the pen price.

So: yes, the UK private price of Wegovy has risen over the past year, and if you are wondering whether Wegovy prices are continuing to go up, the answer depends primarily on manufacturer decisions and supply conditions, not on any one provider's margin.

What market prices have looked like, and the honest caveats

Reported UK private prices for Wegovy have varied by dose and provider. As a factual reference point, Eli Lilly's published Mounjaro list-price increase in late 2025 (from roughly £122 to around £330 per four-week pen at the highest dose) illustrates how dramatically manufacturer pricing can shift in a short period, and that precedent is relevant context for anyone watching the semaglutide market. Wegovy's own private pricing broadly sits in a range of roughly £149 to £375 per month depending on dose and provider, though these figures shift and should be treated as reported estimates rather than guarantees.

Worth noting: NICE's appraisal of semaglutide for weight management sets conditions for NHS use, including a maximum two-year treatment period within specialist services (NICE TA875). NHS availability through specialist routes can affect private demand and, in turn, private pricing. If NHS access broadens, private prices face different competitive pressures, though the timeline for that is uncertain.

People asking whether Wegovy is likely to get cheaper in the near term will find the honest answer is: probably not significantly, and possibly the opposite. For a closer look at the specific factors that could push the cost lower, our page on whether the Wegovy price is going down sets out what would need to change for that to happen. Competition from newer treatments may eventually exert downward pressure, but the trajectory over the past two years has been upward.

What a single transparent price actually includes, and what it often does not

When comparing quotes across providers, the advertised per-pen figure rarely tells the whole story. Common extras that a headline price excludes: an initial consultation charge (sometimes £30–£70), a separate prescription fee, delivery costs (some providers charge per dispatch), and any dose-review or aftercare support fees if your dose changes. A price that looks favourable at the pen level can close the gap quickly once those are counted.

At nume, we are deliberately not the cheapest option in the market. That is a conscious position. What our single price covers: the consultation, the prescription written by a real clinician, the medicine itself, free next-working-day delivery through DPD in a plain unbranded box, and access to our prescribers for aftercare seven days a week. No hidden line items. You can review what we offer on our treatment page, where current pricing is shown clearly, we do not print per-pen prices in body copy, because the right number to look at is the all-in cost.

Our prescribers are GPhC-registered Independent Prescribers. If you want to read about the clinical oversight behind that, our clinical team page gives the detail. The pharmacy itself is registered with the GPhC (premises registration 9012878, verifiable at the GPhC register).

Why cheapest is the wrong test for a prescription medicine

Price is a reasonable thing to investigate. But for a Prescription-Only Medicine dispensed through a cold chain, the question that matters most is not which provider charges the least, it is which one handles the prescription, verification and supply safely. The MHRA has documented large seizures of counterfeit weight-loss pens sold at prices below the legitimate market, some containing dangerous substances. Sellers offering these medicines without a prescription, through social media or unverifiable websites, are a serious red flag.

The practical check is simple: any online pharmacy legally dispensing Wegovy must appear on the GPhC register. If a seller is not there, do not order from them. You can report suspect sellers at the MHRA's Yellow Card scheme, which also accepts reports of suspected side effects.

Those looking at whether prices might fall in the longer run (and what factors would drive that) can read more on our page covering whether the cost of Wegovy is coming down. For a broader look at how Wegovy works and what it involves clinically, our Wegovy overview is the place to start. And if you have already looked into this and want to find out whether you are a candidate for treatment, the next step is a free clinical consultation, speak to our prescribers through the weight-loss treatments page.